In this commentary in Stem Cell Reports, Peter and his two colleagues from pharmaceutical companies Rhiannon Hardwick and Adrian Roth conducted a thought experiment about the drug discovery pipeline. In spite of the rapid development of new models such as induced pluripotent stem cells, spheroids, organoids and organ-on-chip, there exists a lethargy in the adoption of these by the pharmaceutical industry for drug discovery applications. Read more here.
